Dr. Riess is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2279 45th St
Sacramento, CA 95817Phone+1 916-734-5959Fax+1 916-703-5265
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2009 - 2012
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Rutgers Robert Wood Johnson Medical SchoolClass of 2006
Certifications & Licensure
CA State Medical License 2008 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Start of enrollment: 2018 Jun 26
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Start of enrollment: 2019 Apr 16
- Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer Start of enrollment: 2020 Oct 26
Publications & Presentations
PubMed
- Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT.Clemens Mingels, Mohammad H Madani, Fatma Sen, Hande Nalbant, Jonathan W Riess
European Journal of Nuclear Medicine and Molecular Imaging. 2025-03-21 - 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01 - Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.David R Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel J Klempner, Miles C Andrews
Journal for Immunotherapy of Cancer. 2025-02-06
Press Mentions
Commentary: Genetic Components of NSCLC, June 2022June 1st, 2022- Clinical Edge Journal Scan Commentary: Lung Cancer May 2022May 3rd, 2022
- The White Ribbon Project Comes to Cancer Center to Shine Light on Deadliest of CancersAugust 25th, 2021
- Join now to see all
Grant Support
- Cancer biology and pre-clinical studies of BRCAness in Latino gastric tumorsUNIVERSITY OF CALIFORNIA AT DAVIS2023–2028
- University of California and UT Southwestern D-PDTCUNIVERSITY OF CALIFORNIA AT DAVIS2023–2028
- University of California and UT Southwestern D-PDTCUNIVERSITY OF CALIFORNIA AT DAVIS2023–2028
- The role of ARID1A mutations in Latino gastric cancer biology and disparitiesUNIVERSITY OF CALIFORNIA AT DAVIS2023–2028
- The role of ARID1A mutations in Latino gastric cancer biology and disparitiesUNIVERSITY OF CALIFORNIA AT DAVIS2023–2028
- The role of ARID1A mutations in Latino gastric cancer biology and disparitiesUNIVERSITY OF CALIFORNIA AT DAVIS2023–2028
- University of California and UT Southwestern D-PDTCUNIVERSITY OF CALIFORNIA AT DAVIS2023–2028
- A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC PatientsSLOAN-KETTERING INST CAN RESEARCH2021–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
